Dec 1, 2021
The PCROWD Study invites people with precursor conditions to Share samples a few times each year
The PCROWD Study invites people with precursor conditions to Share samples a few times each year when they are collected as part of...
435
Dec 1, 2021
NCT05090566: Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM
Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy NCT05090566: Phase 2: MagnetisMM-4: Umbrella Study of...
238
Dec 1, 2021
NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
bb2121 Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7) KarMMa-7 Relapsed & Refractory Multiple...
998
Dec 1, 2021
What is Myeloma? | Cancer Research UK 2021
What is Myeloma? | Cancer Research UK 2021 Learn more: Cancer Research UK https://www.cancerresearchuk.org/about-cancer/myeloma/about
119
Dec 1, 2021
PE: CRI - Cancer Research Institute: Cellular Therapies: TIL, TCR, CAR T, and NK Cell Therapies
PE: CRI - Cancer Research Institute: Cellular Therapies: TIL, TCR, CAR T, and NK Cell Therapies How Cellular Immunotherapies Are Changing...
276
Dec 1, 2021
NIH: Clinical Trials: Bringing Cancer Research to All Possible Participants
NIH: NATIONAL CANCER INSTITUTE - Clinical Trials: Bringing Cancer Research to All Possible Participants NIH: NATIONAL CANCER INSTITUTE -...
99
Dec 1, 2021
What are the different stages of Multiple Myeloma? REVISED - INTERNATIONAL STAGING SYSTEM (R-ISS)
IMWG Revised International Staging System Multiple Myeloma REVISED - INTERNATIONAL STAGING SYSTEM is based on blood work results and...
308
Dec 1, 2021
Virtual Meeting: 2021 ASCO Annual Meeting: Jun 4, 2021 – Jun 8, 2021
2021 ASCO Annual Meeting: Jun 4, 2021 – Jun 8, 2021 Chicago, IL 2021 ASCO Annual Meeting: Jun 4, 2021 – Jun 8, 2021 Learn more:...
256
Dec 1, 2021
clonoSEQ: Adaptive Biotechnologies - What is Minimal residual disease (MRD)?
What is Minimal residual disease (MRD)? MRD (Minimal Residual Disease) is a small number of malignant plasma cells that remain in the...
286
Dec 1, 2021
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With...
302
Dec 1, 2021
Virtual Conference: Lymphoma, Leukemia & Myeloma Congress - October 19-23, 2021 New York
Virtual Conference: Lymphoma, Leukemia & Myeloma Congress October 19-23, 2021 New York Learn more: https://lymphomaandmyeloma.oncnet.com/
132
Dec 1, 2021
NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL
NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma...
146
Dec 1, 2021
26th Annual International Congress on Hematologic Malignancies®: Leukemias, Lymphomas, and Myeloma
The 26th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma Eden Roc Miami Beach 4525...
129
Dec 1, 2021
NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
CARTITUDE-5 Phase 3 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against...
2,876